Press Releases

Our press releases

• Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003 Jun 22 2021
• Bio-Path Holdings Reports First Quarter 2021 Financial Results May 14 2021
• Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021 May 7 2021
• Bio-Path Announces Publication in Biomedicines Apr 22 2021
• Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting Apr 12 2021
• Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia Apr 5 2021
• Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting Mar 11 2021
• BIO-PATH HOLDINGS REPORTS FULL YEAR 2020 FINANCIAL RESULTS Mar 10 2021
• Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021 Mar 3 2021
• Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock Feb 18 2021